Lilly nabs FDA approval for its blockbuster cancer hopeful ramucirumab

Eli Lilly ($LLY) reached the FDA finish line with its cancer treatment Cyramza (ramucirumab), its star oncology candidate. The Indianapolis-based company nabbed an approval in gastric cancer, for patients whose tumors can't be removed or those whose cancer has spread after previous treatment. Peak sales? As high as $1.3 billion, analysts say. Release | Report

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.